Single Cell Acute Leukemia Analysis
ConditionAcute Myeloid Leucemia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique Hopitaux De Marseille
About this trial
Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.
Eligibility criteria
Qualifiers
Adult patient
Patient who has received information about the study and has not expressed opposition,
Patients who are beneficiaries of a social security plan,
Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.
Disqualifiers
Persons who do not understand the French language if there is no translator available to translate for them.
Absence of circulating blastosis.
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov